- Home
- ESPR vs NPCT Comparison
ESPR vs NPCT Comparison
Compare ESPR & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- NPCT
- Stock Information
- Founded
- ESPR 2008
- NPCT 2020
- Country
- ESPR United States
- NPCT United States
- Employees
- ESPR N/A
- NPCT N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- ESPR Health Care
- NPCT Finance
- Exchange
- ESPR Nasdaq
- NPCT Nasdaq
- Market Cap
- ESPR 305.0M
- NPCT 311.7M
- IPO Year
- ESPR 2013
- NPCT N/A
- Fundamental
- Price
- ESPR $1.57
- NPCT $10.69
- Analyst Decision
- ESPR Buy
- NPCT
- Analyst Count
- ESPR 7
- NPCT 0
- Target Price
- ESPR $6.36
- NPCT N/A
- AVG Volume (30 Days)
- ESPR 4.0M
- NPCT 107.1K
- Earning Date
- ESPR 03-04-2025
- NPCT 01-01-0001
- Dividend Yield
- ESPR N/A
- NPCT 9.82%
- EPS Growth
- ESPR N/A
- NPCT N/A
- EPS
- ESPR N/A
- NPCT N/A
- Revenue
- ESPR $332,314,000.00
- NPCT N/A
- Revenue This Year
- ESPR $5.51
- NPCT N/A
- Revenue Next Year
- ESPR $1.42
- NPCT N/A
- P/E Ratio
- ESPR N/A
- NPCT N/A
- Revenue Growth
- ESPR 185.66
- NPCT N/A
- 52 Week Low
- ESPR $1.47
- NPCT $8.58
- 52 Week High
- ESPR $3.94
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- ESPR 35.13
- NPCT 43.81
- Support Level
- ESPR $1.47
- NPCT $10.76
- Resistance Level
- ESPR $1.61
- NPCT $10.96
- Average True Range (ATR)
- ESPR 0.12
- NPCT 0.11
- MACD
- ESPR -0.00
- NPCT -0.02
- Stochastic Oscillator
- ESPR 1.28
- NPCT 4.88
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.